Safety and efficacy of 4 difference direct oral anticoagulants, dabigatran, rivaroxaban, apixaban and edoxaban in real-world clinical practice: a single center prospective all-comer registry

Safety and efficacy of 4 difference direct oral anticoagulants, dabigatran, rivaroxaban, apixaban and edoxaban in real-world clinical practice: a single center prospective all-comer registry - DIRECT registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033283

Enrollment

2000

Registered

2018-07-04

Start date

2019-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-valvular atrial fibrillation

Interventions

None listed

Sponsors

Department of Cardiology, Osaka Police Hospital

Lead Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-valvular atrial fibrillation

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The primary safety end point was the occurrence of clinically significant bleeding [a composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and any minor bleeding]. The primary efficacy end point was the occurrence of a major adverse cardiovascular event (a composite of death from cardiovascular causes, myocardial infarction, or stroke).	—

Secondary

Measure	Time frame
Secondary endpoints were each individual components of the primary safety and efficacy endpoints.	—

Countries

Japan

Contacts

Public ContactYohei Sotomi

Osaka Police Hospital Department of Cardiology

sotomiyohei@gmail.com0667716051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026